2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2051 Results of a phase 2 trial evaluating ruxolitinib to improve symptoms in patients with low-risk essential thrombocythemia or polycythemia vera

Chi-Joan How, MD, Yiwen Liu, MS2, Kenneth Bauer, MD3, Roelof Bekendam, MD, PhD4, Brian Carney, MD5, Daniel J DeAngelo, MD, PhD6, Reed E. Drews, MD7, Erin Dunaway8, Jacqueline S. Garcia, MD9, Giovanna Giordano10, Emma Logan, MSN11, Jennifer Lombardi-Story12, Marlise Rachael Luskin, MD, MSCE13, Caitlin Manzi14, Ann Mullally I, MD15, Donna Neuberg, ScD16, Thomas Reardon17, Adina Sweet18, Alyssa L Watson19, Eric Stephen Winer, MD20, Michelle Hyunju Lee, MD21, Rushad Patell, MD22, Gabriela Soriano Hobbs, MD23
1 Brigham and Women's Hospital, Boston, Massachusetts, United States
2 Dana Farber Cancer Institute, Boston, United States
3 Beth Israel Deaconess Medical Center, Boston, United States
4 Beth Israel Deaconess Medical Center, Boston, United States
5 Beth Israel Deaconess Medical Center, Boston, United States
6 Dana Farber Cancer Institute, Boston, United States
7 Beth Israel Deaconess Medical Center, Boston, United States
8 Massachusetts General Hospital, Boston, United States
9 Dana Farber Cancer Institute, Boston, United States
10 Beth Israel Deaconess Medical Center, Boston, United States
11 Beth Israel Deaconess Medical Center, Boston, United States
12 Massachusetts General Hospital, Boston, United States
13 Dana Farber Cancer Institute, Boston, United States
14 Massachusetts General Hospital, Boston, United States
15 Stanford University School of Medicine, Stanford, United States
16 Dana Farber Cancer Institute, Boston, United States
17 Dana Farber Cancer Institute, Boston, United States
18 Dana Farber Cancer Institute, Boston, United States
19 Massachusetts General Hospital, Boston, United States
20 Dana Farber Cancer Institute, Boston, United States
21 Massachusetts General Hospital, Boston, United States
22 Beth Israel Deaconess Medical Center, Boston, United States
23 Massachusetts General Hospital, Boston, United States

Introduction: Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPNs) associated with thrombotic risk and disease progression. Cytoreduction is recommended for high-risk patients to reduce cardiovascular events, but many low-risk patients experience substantial symptoms driven by inflammatory cytokines from activated JAK/STAT signaling. Ruxolitinib, a JAK1/2 inhibitor, improves symptoms in myelofibrosis and second line high-risk PV patients. We hypothesized that ruxolitinib would improve symptoms in low-risk ET and PV patients who experience significant MPN-related symptoms.

Methods: This is a multi-center, non-randomized, two-stage phase 2 trial evaluating ruxolitinib at a starting dose of 10 mg twice daily in low-risk but symptomatic ET and PV patients (NCT04644211).

Eligible patients were adults (age >18) diagnosed with ET or PV by World Health Organization 2016 criteria. ET patients were very-low, low, or intermediate risk by Revised International Prognostic Score for Thrombosis (R-IPSET), and PV patients were low-risk by National Comprehensive Cancer Network (NCCN) criteria. Patients must have a baseline MPN Symptom Assessment Form (SAF) Total Symptom Score (MPN10)>10 with at least one individual component of the MPN10>5. Prior cytoreduction was allowed if its primary indication was for symptom control.

The primary endpoint is symptom response, defined as >50% improvement of baseline to week 12 MPN10.  Patients completed daily MPN10s during prespecified assessment windows every 2 weeks through week 12; mean scores were used for analysis. Secondary endpoints include hematologic response by International Working Group criteria; % change in spleen volume; and patient-reported outcomes including MPN SAF, modified Patient-Reported Outcomes Measurement Information System (mPROMIS-57) Symptom Interference, Patient Health Questionnaire-2 (PHQ-2), and Patient Global Impression of Change (PGIC). Correlative analyses include changes in inflammatory cytokines and driver mutation variant allele fraction.

The study employed Simon two-stage design. After the first 15 patients were enrolled, the prespecified criteria for proceeding to Stage 2 were met, and an additional 15 patients were enrolled. The study is considered promising if there are ≥6 responses among 30 patients.

Results: As of 7/11/26, 30 patients (10 PV, 20 ET) were enrolled across 3 centers. Median age was 52 years (range: 19-71); 80% were female and 77% were White. Among the 20 ET patients, 7 were very-low-risk, 11 were low-risk, and 2 were intermediate risk; all PV patients were low-risk. 13 patients had received prior cytoreductive therapy. 20 patients had JAK2 V617F, 6 CALR, 2 MPL, and 2 were triple negative. 12 patients had splenomegaly at baseline (n = 29); mean spleen volume in the cohort was 400 mL (SD 210, n = 24). Median C1D1 blood counts (n=30) were WBC 8.78 K/uL (IQR 7.04-10.44), Hct 41.6% (IQR 38.4-44.3%), and platelets 679 K/uL (IQR 461-970).

The total baseline MPN10 score was 32.4 (SD 14.5, n = 30), with higher scores in PV vs ET (35.8 vs 30.7). The mean baseline MPN-SAF score was 7.18 (SD 2.37, n = 28 for MPN-SAF items) for worst fatigue, 6.36 (SD 2.59) for usual fatigue, and 5.64 (SD 2.38) for current fatigue. The highest mean baseline MPN-SAF scores for non-fatigue symptoms included inactivity (mean 5.18, SD 2.83), difficulty with concentration (mean 4.82, SD 2.93) and difficulty sleeping (mean 4.68, SD 3.46). On the mPROMIS-57 (n=27 for mPROMIS-57 items), 52%, 48%, and 52% of patients reported at least “quite a bit” of interference with day-to-day activities, work around home, and enjoyment of life, respectively. 28.6% of patients reported feeling depressed on more than half the days or nearly all days on the baseline PHQ-2 (n = 24).

The last patient initiated C1D1 on 06/23/2026. Per the predefined statistical analysis plan, primary and secondary week 12 efficacy analyses will be performed once all patients have completed the week 12 assessments; full results will be presented at the conference.

Conclusion: In this multicenter phase 2 study, ruxolitinib was evaluated in low-risk but highly symptomatic patients with ET and PV. Baseline assessments demonstrated substantial symptom burden, highlighting an important unmet need. Accrual was successfully completed, with final efficacy and outcome data to be presented at the conference.

Chi-Joan How, MD: PharmaEssentia - Research Funding; Merck - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony)